High Dose Chemotherapy and Autologous Transplant for Neuroblastoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01526603|
Recruitment Status : Recruiting
First Posted : February 6, 2012
Last Update Posted : September 26, 2018
|Condition or disease||Intervention/treatment||Phase|
|Neuroblastoma||Drug: Carboplatin Biological: Autologous stem cell infusion Biological: Granulocyte colony stimulating factor Radiation: Radiation therapy Drug: Isotretinoin (13-cis-retinoic acid) Drug: Melphalan Drug: Etoposide||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Rescue for Neuroblastoma: Standard of Care Considerations|
|Actual Study Start Date :||March 28, 2012|
|Estimated Primary Completion Date :||February 2019|
|Estimated Study Completion Date :||February 2020|
Patients Treated for Neuroblastoma
According to patient weight and renal function, consolidation chemotherapy using various doses of Melphalan, Etoposide, and Carboplatin followed by autologous stem cell infusion and serial post-transplant Granulocyte Colony Stimulating Factor, radiation therapy and Isotretinoin maintenance therapy.
Carboplatin intravenously (IV), 425 mg/m2/dose (or if ≤ 12kg, 14.2 mg/kg/dose) once daily x 4 doses on days 7 through 4 pretransplant.
Other Name: Paraplatin
Biological: Autologous stem cell infusion
On day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
Biological: Granulocyte colony stimulating factor
Beginning on day 0 after infusion of the PBSC, patients will receive G-CSF subcutaneously (SQ) or IV (SQ preferred) 5 micrograms/kg once daily and continuing once daily until post-nadir absolute neutrophil count (ANC) > 2000/μL for 3 consecutive days.
Other Name: G-CSF
Radiation: Radiation therapy
It is suggested that patients who have a complete surgical resection of the primary tumor receive 21.6 Gy external beam radiation therapy (EBRT) to the post-induction chemotherapy, pre-operative primary tumor volume. It is suggested that patients who have an incomplete surgical resection of the primary tumor (residual soft tissue mass measuring >1 cm3) will receive 21.6 Gy EBRT to the postinduction chemotherapy, pre-operative primary tumor volume and an additional boost of 14.4 Gy EBRT to the gross residual tumor (total dose 36 Gy to gross residual tumor volume). Radiation should be given after stem cell transplantation and should start no sooner than 28 days post transplant.
Drug: Isotretinoin (13-cis-retinoic acid)
Post-transplant maintenance therapy with cis-RA daily for 14 days every 28 days repeated for 6 months. This phase of the therapy can be initiated by the BMT team and continued by the referring physician. It is recommended to begin Isotretinoin at day 66 post-transplant and no later than day 100. For patients ≤12 kg, isotretinoin (accutane) should be administered at 5.33 mg/kg/dose divided twice daily. For patients >12 kg isotretinoin (accutane) should be administered at 160 mg/m^2/day divided twice a day. Patients should be considered for monoclonal antibody therapy against GD2, such as ch14.18 if such trials are available.
Other Name: Accutane
Melphalan Intravenously (IV), 70 mg/m2/dose (or if ≤ 12 kg, 2.3 mg/kg/dose) once daily x 3 doses on days 7 through 5 pretransplant
Other Name: Alkeran
Etoposide intravenously (IV), 338 mg/m2/dose (or if ≤ 12kg, 11.3 mg/kg/dose) once daily x 4 doses on days 7 through 4 pretransplant
- Number of Patients with Successful Engraftment [ Time Frame: Day 42 ]The time to neutrophil engraftment will be assessed by standard statistical approaches.
- Number of Patients with Disease Free Survival [ Time Frame: 2 Years ]The number of patients alive and disease free will be assessed using standard statistical approaches.
- Overall Survival [ Time Frame: 2 Years ]The number of patients alive will be assessed by standard statistical approaches.
- Number of Patients with Treatment Related Death [ Time Frame: 1 Year ]The rate of treatment related mortality will be assessed by cumulative incidence approach.
- Number of Patients with Disease Free Survival [ Time Frame: 5 Years ]The number of patients alive and disease free will be assessed using standard statistical approaches.
- Overall Survival [ Time Frame: 5 Years ]The number of patients alive will be assessed by standard statistical approaches.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01526603
|Contact: Kim Nelsonfirstname.lastname@example.org|
|United States, Minnesota|
|Masonic Cancer Center, University of Minnesota||Recruiting|
|Minneapolis, Minnesota, United States, 55455|
|Contact: Kim Nelson 612-273-2925 email@example.com|
|Principal Investigator:||Heather Stefanski, MD||Masonic Cancer Center, University of Minnesota|